Bacteriophage Company AmpliPhi Presents Positive Data on Expanded Access Program for Serious S. aureus Infections

Submitted by admin on October 8, 2018 - 10:03am

Source:

CP Wire

News Tags:

Headline:

snippet:

10 of 12 patients achieved treatment success
AB-SA01 was well tolerated with no adverse events attributable to AB-SA01
Initial gene expression data indicate that bacteriophage treatment may downregulate pro-inflammatory genes and upregulate anti-inflammatory genes
AmpliPhi currently has two products in development

Search form